RYBELSUS^® indication

The world's first and only oral GLP-1 RA

RYBELSUS^® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise:

• As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.

• In combination with other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, please refer to the full SmPC¹

Click here↗ for RYBELSUS^® prescribing information

GLP-1 RA=glucagon-like peptide-1 receptor agonist

References

1. Novo Nordisk Limited; GB & NI RYBELSUS^® SmPCs.

UK22RYB00380 | February 2023